Gilead delivers groundbreaking HIV prevention drug to Eswatini & Zambia

The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval

Texas hits Sanofi, Bristol-Myers Squibb with lawsuit over blood thinner drug efficacy

Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people

Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance

Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma

Lupin launches long-acting Risperidone in US

This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology

Venus Remedies expands ASEAN presence with new drug approvals in Vietnam

Venus Remedies now has 29 active product approvals in Vietnam alone

Amgen confident in US biosimilar market’s strength as sales surge 52%

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion

Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development